Apellis CEO’s Insider Sale: Routine Tax Move, No Red Flag for Investors
Apellis CEO sells shares for tax reasons, not a red flag—company remains strong in rare‑disease biotech with positive analyst sentiment and solid valuation.
4 minutes to read
Apellis Pharmaceuticals Inc
Apellis Insider Selling Surge Signals Volatility Ahead – Investors Urged to Watch
Apellis insider sales spike amid market volatility—executive trades exceed 30% in six months, raising caution while investors watch regulatory and pipeline news.
3 minutes to read
Apellis Insider Buys 888 Shares at $14.95, Signaling Confidence Ahead of JP Morgan Conference
Apellis insider buy: Watson David O. snaps up 888 shares at $14.95 amid bullish trend, signaling confidence ahead of J.P. Morgan Healthcare Conference.
3 minutes to read